Unadjusted incidence rate for major outcomes in patients treated with statins alone or statins plus n-3 PUFA^*.

*<p>Number are expressed as incidence per 100 patients-year of follow-up.</p

Summary of main baseline characteristics.

<p>Summary of main baseline characteristics.</p

Baseline characteristics and outcomes in paired-matched population.

*<p>All p values are for McNemar’s test.</p

Kaplan-Meier survival curves of the effects of statins plus n-3 PUFA as compared with statins alone on overall survival.

<p>Kaplan-Meier survival curves of the effects of statins plus n-3 PUFA as compared with statins alone on overall survival.</p

Association between combination therapy and mortality among subsets of patients.

<p>Association between combination therapy and mortality among subsets of patients.</p

Kaplan-Meier survival curves of the effects of statins plus n-3 PUFA as compared with statins alone on death or myocardial infarction (A), death or atrial fibrillation (B) and death or congestive heart failure (C).

<p>Kaplan-Meier survival curves of the effects of statins plus n-3 PUFA as compared with statins alone on death or myocardial infarction (A), death or atrial fibrillation (B) and death or congestive heart failure (C).</p

Discrimination and reclassification analysis.

<p>Discrimination and reclassification analysis.</p

Hazard Ratios for overall mortality adjusted by age and sex, according to DDCI.

<p>Hazard Ratios for overall mortality adjusted by age and sex, according to DDCI.</p

Flow-chart of the study.

<p>Flow-chart of the study.</p

Assignment of weights in the construction of DDCI through a time-to-death multivariate Cox proportional hazards regression.

<p>Assignment of weights in the construction of DDCI through a time-to-death multivariate Cox proportional hazards regression.</p